Disease · MONDO_0005929
postpartum depression
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. postpartum depression. Diseases, record MONDO_0005929. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005929
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Depression, Postpartum, Maternity blues (disorder), depressive episode with postpartum onset, major depressive episode with peripartum onset, postnatal depression
- Open Targets
- Highest stage of its drugs
- Approval, for 2 of its 30 drugs, from ClinicalTrials.gov, DailyMed, EMA Human Drugs, FDA and TTD
- Open Targets
Drugs30
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BREXANOLONE | CHEMBL207538 | Small molecule | Approval | ClinicalTrials.gov, DailyMed, FDA and TTD | 12 | 9 | 9 | Drugs and targets |
| ZURANOLONE | CHEMBL4105630 | Small molecule | Approval | EMA Human Drugs, FDA and TTD | 8 | 5 | 5 | Drugs and targets |
| SERTRALINE | CHEMBL809 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| ARIPIPRAZOLE | CHEMBL1112 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DESVENLAFAXINE | CHEMBL1118 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| KETAMINE | CHEMBL742 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| FENTANYL | CHEMBL596 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| MEPERIDINE | CHEMBL607 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NITROUS OXIDE | CHEMBL1234579 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| REMIFENTANIL | CHEMBL1005 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 30
See all 30 drugsTargets41
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SLC6A4 | Sodium-dependent serotonin transporter | 5 | Serotonin transporter inhibitor | Phase 3 | https://conductscience.org/library/genes/6532 | Drugs and targets |
| GABRA1 | GABA-A receptor; anion channel | 4 | GABA-A receptor; anion channel positive allosteric modulator | Approval | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRA2 | GABA-A receptor; anion channel | 4 | GABA-A receptor; anion channel positive allosteric modulator | Approval | https://conductscience.org/library/genes/2555 | Drugs and targets |
| GABRA3 | GABA-A receptor; anion channel | 4 | GABA-A receptor; anion channel positive allosteric modulator | Approval | https://conductscience.org/library/genes/2556 | Drugs and targets |
| GABRA4 | GABA-A receptor; anion channel | 4 | GABA-A receptor; anion channel positive allosteric modulator | Approval | https://conductscience.org/library/genes/2557 | Drugs and targets |
| GABRA5 | GABA-A receptor; anion channel | 4 | GABA-A receptor; anion channel positive allosteric modulator | Approval | https://conductscience.org/library/genes/2558 | Drugs and targets |
| GABRA6 | GABA-A receptor; anion channel | 4 | GABA-A receptor; anion channel positive allosteric modulator | Approval | https://conductscience.org/library/genes/2559 | Drugs and targets |
| GABRB1 | GABA-A receptor; anion channel | 4 | GABA-A receptor; anion channel positive allosteric modulator | Approval | https://conductscience.org/library/genes/2560 | Drugs and targets |
| GABRB2 | GABA-A receptor; anion channel | 4 | GABA-A receptor; anion channel positive allosteric modulator | Approval | https://conductscience.org/library/genes/2561 | Drugs and targets |
| GABRB3 | GABA-A receptor; anion channel | 4 | GABA-A receptor; anion channel positive allosteric modulator | Approval | https://conductscience.org/library/genes/2562 | Drugs and targets |
1 to 10 of 41
See all 41 targetsTrials38
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03864614 | A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD) | Phase 3 | 1,515 | 2024-07-18 | Major Depressive Disorder | ZURANOLONE | Its record names the disease | ClinicalTrials.gov |
| NCT02978326 | A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression | Phase 3 | 276 | 2021-12-16 | Postpartum Depression | ZURANOLONE | Its record names the disease | ClinicalTrials.gov |
| NCT04442503 | A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD) | Phase 3 | 200 | 2023-06-22 | Depression, Postpartum | ZURANOLONE | Its record names the disease | ClinicalTrials.gov |
| NCT00602355 | Effectiveness of Sertraline Alone and Interpersonal Psychotherapy Alone in Treating Women With Postpartum Depression | Phase 2 | 162 | 2016-09-21 | Depression, Postpartum | SERTRALINE | Its record names the disease | ClinicalTrials.gov |
| NCT02942004 | A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B) | Phase 3 | 138 | 2019-06-13 | Postpartum Depression | BREXANOLONE | Its record names the disease | ClinicalTrials.gov |
| NCT02942017 | A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C) | Phase 3 | 108 | 2019-06-13 | Postpartum Depression | BREXANOLONE | Its record names the disease | ClinicalTrials.gov |
| NCT03228394 | A Clinical Trial of Intravenous (IV) Ganaxolone in Women With Postpartum Depression | Phase 2 | 91 | 2023-02-08 | Depression, Depressive Disorder, Depression, Postpartum, Behavioral Symptoms, Mood Disorders, Mental Disorders, Puerperal Disorders, Pregnancy Complications, Postpartum, PPD | GANAXOLONE | Its record names the disease | ClinicalTrials.gov |
| NCT03460756 | A Clinical Trial of Oral Ganaxolone in Women With Postpartum Depression | Phase 2 | 84 | 2023-01-30 | Depressive Disorder, Depression, Depression, Postpartum, Behavioral Symptoms, Mood Disorders, Mental Disorder, Pregnancy Complications, Postpartum Blues, PPD, Postpartum Disorder | GANAXOLONE | Its record names the disease | ClinicalTrials.gov |
| NCT03022526 | CSE v. Epidural for Postpartum Depression | Not applicable | 61 | 2020-08-10 | Depression, Postpartum, Labor Pain | BUPIVACAINE, FENTANYL | Its record names the disease | ClinicalTrials.gov |
| NCT05059600 | A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting | Phase 4 | 52 | 2023-07-19 | Postpartum Depression | BREXANOLONE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 38
See all 38 trialsComparisons in its trials16
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| SAGE-217 50 mg vs Placebo: deaths from any cause | 0 of 98 | 0 of 98 | 196 | NCT04442503 | Trial comparisons |
| SAGE-217 50 mg vs Placebo: serious adverse events | 2 of 98 | 0 of 98 | 196 | NCT04442503 | Trial comparisons |
| SAGE-547 90 μg/kg/h vs Placebo: deaths from any cause | 0 of 51 | 0 of 53 | 104 | NCT02942017 | Trial comparisons |
| SAGE-547 90 μg/kg/h vs Placebo: serious adverse events | 1 of 51 | 0 of 53 | 104 | NCT02942017 | Trial comparisons |
| Combined Spinal Epidural (CSE) vs Epidural: deaths from any cause | 0 of 31 | 0 of 30 | 61 | NCT03022526 | Trial comparisons |
| Combined Spinal Epidural (CSE) vs Epidural: serious adverse events | 0 of 31 | 0 of 30 | 61 | NCT03022526 | Trial comparisons |
| Combined Spinal Epidural (CSE) vs Epidural: Number of Participants Currently Breastfeeding at 2 Days Postpartum (Yes/No) | 22 of 25 | 18 of 28 | 53 | NCT03022526 | Trial comparisons |
| Combined Spinal Epidural (CSE) vs Epidural: Number of Participants Currently Breastfeeding at 6 Weeks Postpartum (Yes/No) | 15 of 20 | 12 of 24 | 44 | NCT03022526 | Trial comparisons |
| Combined Spinal Epidural (CSE) vs Epidural: Number of Participants Currently Breastfeeding at 3 Months Postpartum (Yes/No) | 9 of 15 | 8 of 23 | 38 | NCT03022526 | Trial comparisons |
| SAGE-547 vs Placebo: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 4 of 10 | 8 of 11 | 21 | NCT02614547 | Trial comparisons |
1 to 10 of 16
See all 16 comparisons in its trialsPapers from its trials20
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005929
GET https://conductscience.org/api/diseases/v1/MONDO_0005929/drugs?page=2